Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases
NCT00469937 is a phase 1 interventional trial sponsored by Vanderbilt-Ingram Cancer Center. As of 21 Nov 2026, it was terminated. It studies Lithium carbonate in Brain and Central Nervous System Tumors, Cognitive/Functional Effects and 2 more conditions. The registry lists an enrollment of 9 participants at 3 sites in 1 country. The registry lists a start date of 28 Feb 2006 and a primary completion date of 31 Mar 2009.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00469937 |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | Vanderbilt-Ingram Cancer Center |
| Enrollment | 9 |
| Registered sites | 3 |
| Countries | 1 |
| Conditions | Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Neurotoxicity, and Solid Tumor |
| Drugs | Lithium carbonate |
| Start | 28 Feb 2006 |
| Primary completion | 31 Mar 2009 |
| Study completion | 31 Mar 2009 |
| Last update posted | 28 Feb 2012 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Bo Lu, MD, PhD
Vanderbilt-Ingram Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Vanderbilt-Ingram Cancer Center
Nashville
- Vanderbilt-Ingram Cancer Center - Cool Springs
Nashville
- Vanderbilt-Ingram Cancer Center at Franklin
Nashville
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00469937
Each answer restates registry values shown on this page.
What is NCT00469937?
NCT00469937 is a phase 1 interventional trial sponsored by Vanderbilt-Ingram Cancer Center. It studies Lithium carbonate in Brain and Central Nervous System Tumors, Cognitive/Functional Effects and 2 more conditions.
Who leads NCT00469937?
The registry names Bo Lu, MD, PhD (principal investigator, Vanderbilt-Ingram Cancer Center) as the overall official.
Where does NCT00469937 run?
The registry lists 3 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00469937 study?
The registered drug and biological interventions are Lithium carbonate.
When did NCT00469937 end?
The registry lists a primary completion date of 31 Mar 2009 and a study completion date of 31 Mar 2009. The sponsor last updated the record on 28 Feb 2012.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.